Logo-ijdrc
Int J Drug Res Clin. 2024;2: e1.
doi: 10.34172/ijdrc.2024.e1
  Abstract View: 245
  PDF Download: 164

Review Article

The Nephrotoxicity of Checkpoint Inhibitors: A Mini Review

Fariba Mahmoodpoor 1 ORCID logo, Mohammadreza Ardalan 2, Aygun Nasibova 3, Mahbuba Valiyeva 4, Elham Ahmadian 1* ORCID logo

1 Research Center for Integrative Medicine in Aging, Aging Research Institute,Tabriz University of Medical Sciences, Tabriz, Iran
2 Kidney Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
3 Department of Biophysics and Biochemistry, Baku State University, Baku, Azerbaijan
4 Department of Pharmaceutical Technology and Management, Azerbaijan Medical University, Baku 1022, Azerbaijan
*Corresponding Author: Elham Ahmadian, Email: ahmadian.elham@yahoo.com, Email: ahmadian.elham@yahoo.com

Abstract

Immune checkpoint inhibitors (ICIs) have established promising therapeutic outcomes in the treatment of more than 17 tumors and are being used more frequently. Although these drugs have made progress in cancer treatment over the past ten years, severe immune-related adverse events (irAEs) can be fatal. Nephrotoxicity is less frequent than toxicities that affect the gastrointestinal tract, the skin, and the endocrine system, yet it is frequently underdiagnosed because of its difficulty. The most frequent nephrotoxicity is acute kidney injury (AKI), which is typically linked to acute interstitial nephritis. It is possible for kidney impairment caused by ICIs to manifest in much more varied ways, which may have an impact on the management strategies for therapeutic as well as diagnostic purposes. The current study discussed the most recent ICIs for cancer that have been approved, the risk factors and prevalence of nephrotoxicity, the present knowledge of the pathological mechanisms of AKI, and the management protocols.

Please cite this article as follows: Mahmoodpoor F, Ardalan M, Nasibova A, Mahbuba Valiyeva, Ahmadian E. The nephrotoxicity of checkpoint inhibitors: a mini review. Int J Drug Res Clin. 2024;2: e1. doi: 10.34172/ijdrc.2024.e1
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 246

Your browser does not support the canvas element.


PDF Download: 164

Your browser does not support the canvas element.

Submitted: 10 Jul 2023
Accepted: 11 Dec 2023
ePublished: 21 Feb 2024
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)